相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CD4+ and CD8+ T Cells Can Act Separately in Tumour Rejection after Immunization with Murine Pneumotropic Virus Chimeric Her2/neu Virus-Like Particles
Kalle Andreasson et al.
PLOS ONE (2010)
Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors
Kalle Andreasson et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Novel Multi-Peptide Vaccination In Hla-A2+Hormone Sensitive Patients With Biochemical Relapse of Prostate Cancer
Susan Feyerabend et al.
PROSTATE (2009)
High Frequency of Prostate Antigen-Directed T Cells in Cancer Patients Compared to Healthy Age-Matched Individuals
Ole Forsberg et al.
PROSTATE (2009)
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer
Eric J. Small et al.
BJU INTERNATIONAL (2007)
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials
Elmar A. Joura et al.
LANCET (2007)
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Suzanne M. Garland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor
Karin Tegerstedt et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide
Supriya Perambakam et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy:: The GVAX™ vaccine for prostate cancer
Jonathan W. Simons et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2006)
Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer
David M. Lubaroff et al.
VACCINE (2006)
Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer
E Elkord et al.
INTERNATIONAL IMMUNOLOGY (2005)
A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors
K Tegerstedt et al.
CANCER RESEARCH (2005)
Identification of an immunodominant H-2Db-restricted CTL epitope of human PSA
M Pavlenko et al.
PROSTATE (2005)
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
A Ziada et al.
PROSTATE (2004)
Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study
HS Pandha et al.
BJU INTERNATIONAL (2004)
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
MI Milowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation
NG Chakraborty et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2003)
Murine pneumotropic virus VP1 virus-like particles (VLPs) bind to several cell types independent of sialic acid residues and do not serologically cross react with murine polyomavirus VP1VLPs
K Tegerstedt et al.
JOURNAL OF GENERAL VIROLOGY (2003)
T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes
MJ Turner et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
分享论文
